Suven Life Sciences Limited

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Suven Life Sciences Limited sits in the top decile of US sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count).

12 total trials 2 currently recruiting 9 completed early-phase tilt top decile by trial count

Suven Life Sciences Limited: 12 sponsored US clinical trials, 2 recruiting.

Suven Life Sciences Limited sponsors 12 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 9 completed. 1 of these trials are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cognitive Disorders, with 1 trials.

Top-decile sponsor footprint

Suven Life Sciences Limited ranks in the top decile of sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

12 total, page 1 of 1

RECRUITING Phase 1

Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of SUVN-I6107 In Healthy Participants

NCT06705088
RECRUITING Phase 3

Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type

NCT05397639
ACTIVE NOT RECRUITING Phase 2

Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients

NCT06836063
COMPLETED Phase 2

Study Evaluating Safety and Efficacy of Ropanicant in MDD Patients

NCT06126497
COMPLETED Phase 2

A Study to Evaluate Safety, and Efficacy of SUVN-G3031 (Samelisant) in Patients With Narcolepsy With and Without Cataplexy

NCT04072380
COMPLETED Phase 1

Effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-911 in Healthy Subjects

NCT03551288
COMPLETED Phase 1

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-911 in Healthy Subjects

NCT03155503
COMPLETED Phase 1

A Study to Investigate the Effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-D4010 in Healthy Subjects

NCT03031574
COMPLETED Phase 1

A Study to Investigate the Effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-G3031 in Healthy Subjects

NCT02881294
COMPLETED Phase 2

SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study

NCT02580305
COMPLETED Phase 1

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-D4010 in Healthy Subjects

NCT02575482
COMPLETED Phase 1

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-G3031 in Healthy Subjects

NCT02342041

Phase Distribution

PhaseTrial count
Phase 1 7
Phase 2 4
Phase 3 1

Therapeutic Areas

Cognitive Disorders 1
Alzheimer's Type Dementia 1
Agitation 1
Major Depressive Disorder (MDD) 1
Healthy 1

What is open in the Suven Life Sciences Limited pipeline

2 recruiting of 12 indexed (17% open); 9 completed (75%).

Phase mix: 1 late (III/IV) vs 11 early (I/II) (early-phase heavy).

Top condition: Cognitive Disorders (1 trial), 4 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Suven Life Sciences Limited: open-pipeline peers nationwide

Peers matched on 12 registered trials and 17% open enrollment, not the therapeutic-area sidebar.

Suven Life Sciences Limited sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 468101214 0%5%10%15%20% Total trials Recruiting share Suven Life Sciences LimitedAlachua Government ServicesAllergy TherapeuticsAmpio Pharmaceuticals.AngiodynamicsAdageneAgendiaAkamis BioAnthos Therapeutics
Suven Life Sciences Limited sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Suven Life Sciences Limited sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 12 trials (± recruiting share)

Sponsors near 17% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Suven Life Sciences Limited page

12 registered trials is a research-attention snapshot, not an endorsement of Suven Life Sciences Limited or any single study.

  • 2 of Suven Life Sciences Limited's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Cognitive Disorders is the condition Suven Life Sciences Limited studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cognitive Disorders trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Suven Life Sciences Limited pipeline card: 12 registered trials from official public datasets.Report a data error.